Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.34 |
| ▸ | APAF1 | O14727 | 4/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 3/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29491151 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL29491171 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL22650746 | 0.77 | SMN1; SMN2 (0.45) | SMN1; SMN2CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL22650373 | 0.71 | SMN1; SMN2 (0.39) | SMN1; SMN2CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL22650600 | 0.68 | MAPK14 (0.40) | SMN1; SMN2CDK1CDK2L3MBTL1APAF1 | |
| SCHEMBL29491131 | 0.68 | MAPK14 (0.40) | SMN1; SMN2CDK1CDK2L3MBTL1APAF1 | |
| SCHEMBL22650372 | 0.67 | SMN1; SMN2 (0.36) | SMN1; SMN2CDK2CDK5CDK5R1HTR3A | |
| SCHEMBL22650364 | 0.67 | CDK4 (0.37) | SMN1; SMN2CDK2CDK5CDK5R1HTR3A | |
| SCHEMBL19397176 | 0.67 | SMN1; SMN2 (0.51) | SMN1; SMN2CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL20600683 | 0.66 | SMN1; SMN2 (0.46) | SMN1; SMN2CDK1CCNB1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325544-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250275971-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-12285429-B2 | CDK inhibitors | GENENTECH, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20240066031-A1 | CDK INHIBITORS | GENENTECH, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240066031-A1 | CDK INHIBITORS | GENENTECH, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240066031-A1 | CDK INHIBITORS | GENENTECH, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240033264-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2024-02-01 | — | — | US | disclosed |
| US-20230174512-A1 | CDK INHIBITORS | GENENTECH, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174512-A1 | CDK INHIBITORS | GENENTECH, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174512-A1 | CDK INHIBITORS | GENENTECH, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240033264-A1 | CDK INHIBITORS | CDK9, CDKL1, CDK3 | SMN1; SMN2 2631/4885CDK1 5/4885CCNB1 39/4885 |
| US-20240066031-A1 | CDK INHIBITORS | CDK9, CDKL1, CDK3 | SMN1; SMN2 2631/4885CDK1 5/4885CCNB1 39/4885 |
| US-12285429-B2 | CDK inhibitors | CDK9, CDK3, CDKL1 | SMN1; SMN2 2470/4885CDK1 5/4885CCNB1 40/4885 |
| US-20250325544-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | SMN1; SMN2 2041/4885CDK1 4/4885CCNB1 45/4885 |
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | SMN1; SMN2 2350/4885CDK1 7/4885CCNB1 42/4885 |
| US-20230174512-A1 | CDK INHIBITORS | CDK9, CDKL1, CDK3 | SMN1; SMN2 2631/4885CDK1 5/4885CCNB1 39/4885 |
| US-20250275971-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | SMN1; SMN2 2041/4885CDK1 4/4885CCNB1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.